NEW YORK, NY / ACCESSWIRE / July 5, 2017 / Shares of both Opexa Therapeutics and Prana Biotechnology saw a big trading day on Monday. Opexa shares exploded after traders found out that the company would be merging with Texas company Acer Therapeutics that is developing drugs to fight ultra-rare diseases. Prana Biotechnology also stormed ahead after reporting positive clinical results on its novel compound PBT434.

RDI Initiates Coverage on:

Opexa Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=OPXA

Prana Biotechnology Limited
https://ub.rdinvesting.com/news/?ticker=PRAN

Opexa Therapeutics, Inc. was a huge winner on Monday with the stock closing up a staggering 76.92% on incredible volume compared to usual. The big move came after news revealed that Acer Therapeutics would go public through a reverse merger with Opexa. Acer is a biotech company that is developing drugs for ultra-rare diseases. Specifically, Acer is developing a drug that is to treat maple syrup urine disease (MSUD), a rare disease where the body cannot metabolize certain amino acids. There have yet to be any approved treatments for this disease. Shares of the combined company will keep Acer's name and will trade under the ticker symbol "ACER." Acer CEO Chris Schelling will lead the combined company. The merger subject to approval from shareholders is expected to close in the third quarter.

Access RDI's Opexa Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=OPXA

Prana Biotechnology Limited's shares closed up 26.20% on Monday on nearly 2.4 million shares traded. The average volume for the stock is around 37,860 shares. The big move was a result of Prana revealing favorable clinical results. The company said that its novel compound PBT434 was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. According to Prana, "Novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease." PBT434 has shown to lower levels of alpha-synuclein, which is a brain protein that is believed to be connected in the pathogenesis of Parkinson's disease. The novel compound has successfully prevented the loss of nerve cells in the region of the brain that is primarily affected by Parkinson's disease.

Access RDI's Prana Biotechnology Research Report at:
https://ub.rdinvesting.com/news/?ticker=PRAN

Our Actionable Research on Opexa Therapeutics, Inc. (NASDAQ: OPXA) and Prana Biotechnology Limited (NASDAQ: PRAN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com